A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

Completed · Phase 1

Conditions studied: Metastatic Breast Cancer

In brief

The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.

Key facts

Study ID: NCT03955939
Run by: Eli Lilly and Company
People needed: 5
Starts: 2019-08-02
Expected to finish: 2020-05-14
Last updated by the study team: 2020-06-01

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Participant must have hormone receptor positive and HER2 negative metastatic breast cancer
Participant must have progressed on at least 1 line of endocrine therapy and 1 cyclin dependent kinase (CDK)4/6 inhibitor
Participant must be able and willing to undergo mandatory tumor biopsy
Participant must have normal organ function
Participant must be able to swallow capsules

You may not qualify if…

Participant must not have had prior chemotherapy for mBC. Chemotherapy in the adjuvant/neoadjuvant setting is permitted
Participant must not be currently enrolled in a clinical study
Participant must not have another serious medical condition
Participant must not have previously received an aurora kinase inhibitor

Where it is running

City of Hope National Medical Center — Duarte, California, United States
Dana Farber Cancer Institute — Boston, Massachusetts, United States
South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas, United States
Cliniques Universitaires Saint-Luc — Brussels, Belgium
Universitair Ziekenhuis Antwerpen — Edegem, Belgium
Universitair Ziekenhuis Gent — Ghent, Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg — Leuven, Belgium

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.